<DOC>
	<DOCNO>NCT00663312</DOCNO>
	<brief_summary>Parkinson ' disease neurodegenerative disorder characterise bradykinesia , rigidity , rest tremor postural instability . Dopaminergic therapy L-Dopa dopamine agonist usually lead dramatic improvement symptom , disease progression nevertheless remain inevitable . Bilateral Deep brain stimulation subthalamic nucleus ( STN ) lead spectacular clinical improvement patient motor complication consider gold standard surgical treatment . However , surgery induces post-operative body weight gain may limit benefit technique induce critical metabolic disorder profound alteration central control energy metabolism . Previous data seem show glucose metabolism also alter . The aim prospective study identify STN stimulation could modify glucose metabolism regulation especially endogen glucose production ( liver ) Hypothalamus able detect glucose concentration variation control/adjust glucose level modulate hepatic glucose production . As hypothamus STN anatomically close , hypothesise STN stimulation could modulate hypothalamus function consequently modify glucose production .</brief_summary>
	<brief_title>Impact Deep Brain Stimulation Subthalamic Nucleus Hepatic Glucose Production Parkinson 's Disease</brief_title>
	<detailed_description>ilot study 8 patient Inclusion visit : - Clinical examination/ Interview health medical history - Complete UPDRS - Body composition measure DEXA - Biologic check - MMS Protocol : All subject study postabsorptive state 10-h overnight fast . On day experiment , patient receive treatment ( MED OFF ) . One catheter retrogradely insert dorsal vain use blood sample . A second catheter insert controlateral arm tracer infusion . A continuous infusion D-6,6 2H2 glucose ( 0,05mg/kg/h ) perform 6 hour ( prim dose 0,05 mg/kg tracer ) . The first 3 hour , patient study without stimulation ( STIM OFF ) ; last 3 hour stimulator actuate ( STIM ON ) . Blood sample regularly collect 2H2 glucose enrichment determination , insulin , glucose glucagon plasma concentration analysis .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Hypnotics Sedatives</mesh_term>
	<criteria>Inclusion criterion : Age : 1870 year Patient idiopathic Parkinson 's disease accord criterion `` Parkinson 's Disease Society Brain Bank '' ( Hughes et al. , 1992 ) Patient treat deep brain stimulation accord French consensus conference treatment Parkinson 's disease ( Consensus Conference Proceeding , 2000 ) Effect stimulation 50 % Weight gain &gt; 5 % ( surgery compare surgery ) MMS &gt; 24/30 No treatment modification 7 day inclusion Affiliation social security Agreement patient Exclusion criterion : Patient treat antibiotic , AINS , AIS treatment could interfere protocol Patients significant heart , respiratory , psychiatric , metabolic , hepatic , kidney disease ; diabetes , heart deficiency , chronic kidney deficiency , untreated thyroid disease â€¦ Patients metabolic and/or biological anomaly Pregnant woman Medical chirurgical previous history could interfere protocol Alcohol ( &gt; 30g/day ) ; Tobacco ( &gt; 10 cigarettes/day ) Participation study time</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Idiopathic Parkinson 's disease</keyword>
	<keyword>Deep Brain stimulation</keyword>
	<keyword>Hepatic glucose production</keyword>
	<keyword>Insulin</keyword>
	<keyword>Weight gain</keyword>
	<keyword>Patient Idiopathic Parkinson 's disease</keyword>
</DOC>